Zobrazeno 1 - 10
of 12
pro vyhledávání: '"S. Vaultier"'
Autor:
M. O. Beyne-rauzy, D. Vassilieff, Lionel Adès, Stéphane Cheze, Pierre Fenaux, Sophie Park, L. Voillat, Jean-François Bernard, F. Hamza, M.C. Quarre, Claude Gardin, Lionel Mannone, S. Vaultier, Laurence Legros, P. Agape, Francois Dreyfus, Stéphane Giraudier
Publikováno v:
British Journal of Haematology. 133:513-519
An open-label, phase II non-randomised trial was conducted with darbepoetin (DAR), an erythropoiesis-stimulating factor with prolonged half-life, at a weekly dose of 300 mug subcutaneously in 62 anaemic patients with myelodysplastic syndrome (MDS) wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7a66898dbe902375370ee64a5ae783b
https://doi.org/10.1111/j.1365-2141.2006.06070.x
https://doi.org/10.1111/j.1365-2141.2006.06070.x
Autor:
P. Marchand G. Fouillet Y. Berthier J. Douki F. Hassine F. Gmouh S. Vaultier M., Dubois, DUBOIS, Philippe, Marchand, Gilles, Fouillet, Yves, Berthier, Jean, Douki, Thierry, Hassine, Fatima, Gmouh, Saïd, Vaultier, Michel
Publikováno v:
Analytical Chemistry
Analytical Chemistry, American Chemical Society, 2006, 78 (14), pp.4909-17. ⟨10.1021/ac060481q⟩
Analytical Chemistry, 2006, 78 (14), pp.4909-17. ⟨10.1021/ac060481q⟩
Analytical Chemistry, American Chemical Society, 2006, 78 (14), pp.4909-17. ⟨10.1021/ac060481q⟩
Analytical Chemistry, 2006, 78 (14), pp.4909-17. ⟨10.1021/ac060481q⟩
A powerful approach combining a droplet-based, open digital microfluidic lab-on-a-chip using task-specific ionic liquids as soluble supports to perform solution-phase synthesis is reported as a new tool for chemical applications. The negligible volat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2386c4a9b62608631fbf197c1eeda95f
https://hal.archives-ouvertes.fr/hal-00097914
https://hal.archives-ouvertes.fr/hal-00097914
Autor:
Agnès Guerci, M.P. Chaury, E. Berger, Stéphane Courby, I. Coulibaly, Aude Charbonnier, Aspasia Stamatoullas, Pierre Fenaux, Shanti Natarajan, Francois Dreyfus, Stéphane Cheze, Gabriel Etienne, A. Lescoute, Norbert Vey, S. Vaultier, Laurence Legros, Christophe Ravoet
Publikováno v:
Blood. 110:1453-1453
Background: We (Blood.2006;107:1156) and others showed that marrow cells from high-risk MDS patients exhibit constitutive NF-kB activation. Bortezomib (BOR) is a specific inhibitor of NF-kB with limited efficacy when used alone in AML but which is po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c33fa345a7bae48718d0858a54d7687
https://doi.org/10.1182/blood.v110.11.1453.1453
https://doi.org/10.1182/blood.v110.11.1453.1453
Autor:
Caroline Elie, Francois Dreyfus, Achille Aouba, Pierre Fenaux, Agnès Guerci, Frédéric Bauduer, Martine Gardembas, Jerome Tamburini, D. Vassilief, Christian Berthou, Didier Bouscary, M.C. Quarre, S. Vaultier, Laurence Legros, Aspasia Stamatoullas, Laurence Sanhes, Jean-Jacques Sotto, Odile Beyne-Rauzy
Publikováno v:
Blood. 108:2673-2673
Background: Thal has shown some efficacy in low risk MDS, but with dose-limiting toxicity requiring discontinuation in > 50% pts (Bouscary D, BJH, 2005, 131, 609 and other groups). Thus we assessed Thal at lower dose in such MDS. Methods: From Jan 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d56397a1549b0c95dc16fea61763f98
https://doi.org/10.1182/blood.v108.11.2673.2673
https://doi.org/10.1182/blood.v108.11.2673.2673
Autor:
Stéphane Cheze, Aspasia Stamatoullas, Francois Dreyfus, Norbert Vey, Pierre Fenaux, A. Kolb, S. Vaultier, Laurence Legros, Martine Gardembas, Borhane Slama, Ghandi Damaj, Frédéric Bauduer, Hesham Mohamed, E. Berger, M.C. Chaury, F. Hamza, Richard Delarue, D. Vassilief, Xavier Thomas, Odile Beyne-Rauzy, Lionel Adès, Agnès Guerci
Publikováno v:
Publons
Recombinant EPO, when used alone at 60 000 UI/ w, improves anemia in 25 to 30 % of low risk MDS, mainly when serum EPO level is low, and is ineffective on other cytopenias. A previous study (Blood2002,99:1578) suggested that the addition of ATRA to E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1569631a8394b0e65eaf25dacdcae2de
https://doi.org/10.1182/blood.v106.11.2537.2537
https://doi.org/10.1182/blood.v106.11.2537.2537
Autor:
Hervé Dombret, Françoise Picard, Pierre Fenaux, Michel Tulliez, S. Vaultier, Jean Feuillard, Stéphane Cheze, M. Guesnu, Nicole Casadevall, C. Hababou, Francois Dreyfus, M.J. Grange, Lydia Roy, Françoise Isnard, Borhane Slama, Eliane Duchayne, Odile Beyne-Rauzy, Michèle Imbert
Publikováno v:
Leukemia Research. 29:S31
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::946e097d678980decd541786a0ed7343
https://doi.org/10.1016/s0145-2126(05)80083-9
https://doi.org/10.1016/s0145-2126(05)80083-9
Autor:
Stéphane Cheze, M.C. Quarre, Pierre Fenaux, D. Vassilieff, M. O. Beyne-rauzy, Francois Dreyfus, S. Park, Jean-François Bernard, S. Vaultier, L. Mannone, P. Agape
Publikováno v:
Leukemia Research. 29:S24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a285f928f16ea35306d7ff54e28032a
https://doi.org/10.1016/s0145-2126(05)80064-5
https://doi.org/10.1016/s0145-2126(05)80064-5
Autor:
Stéphane Cheze, J J Kiladjian, L. Voilliat, D. Vassilief, P. Agape, E. Rosenthal, Lionel Mannone, M.C. Quarre, Francois Dreyfus, Mo Beyne-Rouzy, Jean-François Bernard, Sophie Park, S. Vaultier, F. Hamza, Pierre Fenaux, Stéphane Giraudier, C. Gardin
Publikováno v:
Blood. 104:69-69
Background : Recombinant Erythopoietin (EPO) alfa or beta, when used alone at 10 to 20 000 units, three times weekly, improves anemia in 25 to 30 % of low risk MDS. By combining G-CSF to EPO, the response rate increases to 40 to 45 %. Darbopoietin al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c677bbc38dcf651080cb63569b70480
https://doi.org/10.1182/blood.v104.11.69.69
https://doi.org/10.1182/blood.v104.11.69.69
Autor:
O. Beyne Rouzy, Achille Aouba, Beatrice Mahe, Pierre Fenaux, Francois Dreyfus, C. Gardembas, Frédéric Bauduer, D. Vassilief, Laurence Sanhes, S. Vaultier, Laurence Legros, M.C. Quarre, Agnès Guerci, Aspasia Stamatoullas, Christian Berthou, Didier Bouscary, Jean-Jacques Sotto
Publikováno v:
Blood. 104:1438-1438
We conducted a phase II trial of thalidomide in patients with low risk MDS issued from the GFM. 82 patients were included from january 2003 to june 2004: 38 RA, 19 RARS, 21 RAEB We suggest that thalidomide should be used at 50 or 100mg/day only in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42b7775cd2ee811c79074e8a4f49dc9a
https://doi.org/10.1182/blood.v104.11.1438.1438
https://doi.org/10.1182/blood.v104.11.1438.1438
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.